Celltrion Inc represents values of innovation, growth, and commitment. The company's corporate philosophy revolves around advancing healthcare through the development of biopharmaceuticals and biosimilars. With a focus on research and development, Celltrion Inc aims to provide effective and affordable treatment options for patients worldwide. By harnessing cutting-edge technology and fostering collaboration, the company strives to make significant contributions to the field of biotechnology. Celltrion Inc's commitment to delivering high-quality products and improving global healthcare standards makes it a prominent player in the pharmaceutical industry.

Celltrion Inc is primarily present in South Korea.

Celltrion Inc has achieved several significant milestones. One notable achievement is the approval and successful launch of their biosimilar drugs, such as Inflectra and Remsima, which have had a positive impact on the healthcare industry. Additionally, Celltrion Inc has made advancements in research and development, particularly in the field of monoclonal antibodies for diseases like cancer and autoimmune disorders. The company has also expanded its global reach by securing strategic partnerships and collaborations with other pharmaceutical companies. These milestones demonstrate Celltrion Inc's commitment to innovation and its ability to produce high-quality biopharmaceutical products.

Celltrion Inc, a renowned biopharmaceutical company based in South Korea, was founded in 2002. With a strong focus on innovation and research, Celltrion has emerged as a global leader in developing and producing biosimilar and innovative biopharmaceuticals. The company has a diverse portfolio of products, including treatments for autoimmune diseases, cancer, and infectious diseases. Celltrion's commitment towards delivering high-quality therapeutics at an affordable cost has garnered international recognition. By leveraging its expertise in biotechnology, Celltrion continues to strive towards improving healthcare standards and ensuring patient well-being. With a successful track record and a dedication to advancing medical advancements, Celltrion Inc has established itself as a prominent player in the pharmaceutical industry.

The main competitors of Celltrion Inc in the market include leading biopharmaceutical companies such as Samsung Bioepis, Pfizer Inc., Amgen Inc., and Roche Holding AG. These companies are actively engaged in the development and commercialization of innovative biologic medicines, which may compete with Celltrion's biosimilar products in various therapeutic areas. Celltrion, however, has established a strong market presence and competitive advantage through its expertise in biosimilars manufacturing, research and development capabilities, and strategic partnerships.

Celltrion Inc is primarily active in the biopharmaceutical industry.

Celltrion Inc's business model focuses on the development, manufacturing, and sales of biopharmaceutical products. As a global biotechnology company, Celltrion specializes in the production of biosimilars, which are highly similar versions of existing biological medicines. By utilizing advanced technology and innovative research, Celltrion aims to provide affordable and accessible treatments to patients worldwide. The company's key strategies involve extensive research and development efforts to expand its product portfolio, strategic collaborations with international partners, and a commitment to enhancing healthcare accessibility. Through its business model, Celltrion Inc strives to contribute to the advancement of the pharmaceutical industry and positively impact patient lives.

مُعامل القيمة السوقية إلى الأرباح لـ Celltrion هو ٤٨٫١٠.

مُعامِل القيمة إلى المبيعات Celltrion هو ٧٫٦٢.

نقاط جودة AlleAktien لـ Celltrion هي 7/10.

المتوقعة Celltrion الإيرادات هي ٣٫٤٨ السيرة الذاتية. KRW.

صافي الربح المتوقعة Celltrion هو ٥٥١٫٣٣ مليارات KRW.

Celltrion Inc. is a Korean biotechnology company that specializes in the research, development, and manufacturing of biological drugs. The company was founded in 2002 and is headquartered in Incheon, South Korea. Celltrion Inc. is involved in various business areas, including the development of biosimilars, distribution of biologics, and development of antibiotics.

يوزع Celltrion أرباحًا قدرها ٣٦٠٫٥٨ KRW من خلال 1 عمليات توزيع موزعة على مدار السنة.

Celltrion يوزع أرباحًا 1 مرة في السنة.

الرمز الدولي للأوراق المالية الخاص بـCelltrion هو KR7068270008.

رمز WKN لـ Celltrion هو A0RM6K.

الرمز المُختصر لـ Celltrion هو 068270.KS.

خلال آخر 12 شهراً، دفعت Celltrion توزيعات أرباح بقيمة ٥٠٠٫٠٠ KRW . وهذا يعادل عائد توزيعات أرباح يقارب ٠٫٢٧ %. ومن المتوقع أن تدفع Celltrion خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٥٥٧٫٢٥ KRW.

نسبة توزيعات الأرباح الحالية لـ Celltrion هي ٠٫٢٧ %.

Celltrion يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر يناير, يناير, يناير, يناير.

Celltrion دفعت توزيعات الأرباح كل عام خلال الـ6 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٥٥٧٫٢٥ KRW. وهذا يعادل عائد توزيعات أرباح قدره ٠٫٣٠ %.

Celltrion يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٥٠٠ KRW من Celltrion المُعلن عنها في ١‏/٣‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/١٢‏/٢٠٢٣.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/٣‏/٢٠٢٤.

في العام 2023، وزعت Celltrion ٣٦٠٫٥٧٧ KRW كأرباح أسهم.

يتم توزيع أرباح Celltrion بالعملة KRW.